1. Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody
- Author
-
Masakazu Murayama, Masahiro Hosonuma, Atsuo Kuramasu, Sei Kobayashi, Akiko Sasaki, Yuta Baba, Yoichiro Narikawa, Hitoshi Toyoda, Junya Isobe, Eiji Funayama, Kohei Tajima, Aya Sasaki, Yuki Maruyama, Yoshitaka Yamazaki, Midori Shida, Kazuyuki Hamada, Yuya Hirasawa, Toshiaki Tsurui, Hirotsugu Ariizumi, Tomoyuki Ishiguro, Risako Suzuki, Ryotaro Ohkuma, Yutaro Kubota, Atsushi Horiike, Takehiko Sambe, Mayumi Tsuji, Satoshi Wada, Shinichi Kobayashi, Toshikazu Shimane, Takuya Tsunoda, Hitome Kobayashi, Yuji Kiuchi, and Kiyoshi Yoshimura
- Subjects
Medicine ,Science - Abstract
Abstract The low response rate of immune checkpoint inhibitors (ICIs) is a challenge. The efficacy of ICIs is influenced by the tumour microenvironment, which is controlled by the gut microbiota. In particular, intestinal bacteria and their metabolites, such as short chain fatty acids (SCFAs), are important regulators of cancer immunity; however, our knowledge on the effects of individual SCFAs remains limited. Here, we show that isobutyric acid has the strongest effect among SCFAs on both immune activity and tumour growth. In vitro, cancer cell numbers were suppressed by approximately 75% in humans and mice compared with those in controls. Oral administration of isobutyric acid to carcinoma-bearing mice enhanced the effect of anti-PD-1 immunotherapy, reducing tumour volume by approximately 80% and 60% compared with those in the control group and anti-PD-1 antibody alone group, respectively. Taken together, these findings may support the development of novel cancer therapies that can improve the response rate to ICIs.
- Published
- 2024
- Full Text
- View/download PDF